NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional ...
The global demand for effective obesity treatments has been surging, with a market size projected to reach USD 60.53 billion ...
Washington retailers can no longer use receipt paper containing a chemical known to cause infertility. Beginning this month, ...
Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its ...
News-Medical.Net on MSN
AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
Automation and AI are revolutionizing the pharmaceutical industry, optimizing technical development and enabling faster, more ...
The Gregg Wadley College of Science & Health Professions at Northeastern State University announced its Spring 2026 Biology and Chemistry Seminar Series, running from Jan. 29 through ...
An image with three panels, all tinted green. In one panel, a woman wearing protective clothing, goggles, gloves, and hair covering holds a clipboard in one arm and reaches with the other toward a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results